Wird geladen...
Recovery from COVID-19 in a B-cell-depleted multiple sclerosis patient
Approximately 200,000 multiple sclerosis (MS) patients worldwide receive B-cell-depleting immunotherapy with rituximab (anti-CD20), which eliminates the ability to generate an antibody response to new infections. As severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)–specific antibodies mig...
Gespeichert in:
| Veröffentlicht in: | Mult Scler |
|---|---|
| Hauptverfasser: | , , , , , |
| Format: | Artigo |
| Sprache: | Inglês |
| Veröffentlicht: |
SAGE Publications
2020
|
| Schlagworte: | |
| Online Zugang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7502978/ https://ncbi.nlm.nih.gov/pubmed/32762494 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/1352458520943791 |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|